Status:
TERMINATED
Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia
Lead Sponsor:
German CLL Study Group
Conditions:
Prolymphocytic Leukemia
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividin...
Detailed Description
OBJECTIVES: * Determine the overall and progression-free survival of patients with B-cell prolymphocytic leukemia treated with immunochemotherapy comprising fludarabine, cyclophosphamide, and rituxim...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of B-cell prolymphocytic leukemia
- Previously treated disease
- All Binet stages allowed
- PATIENT CHARACTERISTICS:
- Life expectancy \> 3 months
- ECOG/WHO performance status 0-3
- PRIOR CONCURRENT THERAPY:
- No more than 3 prior treatment regimens
Exclusion
Key Trial Info
Start Date :
September 1 1999
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2006
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00281931
Start Date
September 1 1999
End Date
October 1 2006
Last Update
September 26 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Helios Klinikum Erfurt
Erfurt, Germany, 99012